| Segment Information The Company operates within targeted markets through three reportable segments for continuing operations: Fintech, Biotech, and Corporate and Other. The following tables present the Company's segment information for the 13 weeks ended March 29, 2025 and March 30, 2024 (in $000's): | | | | | | | | | | | | | Thirteen Weeks Ended | | March 29, 2025 | | March 30, 2024 | | Revenues | | | | | Fintech | $ | 5,514 | | | $ | — | | | Biotech | — | | | — | | | Corporate and other | — | | | — | | | Total Revenues | $ | 5,514 | | | $ | — | | | Gross profit | | | | | Fintech | $ | 2,591 | | | $ | — | | | Biotech | — | | | — | | | Corporate and other | — | | | — | | | Total Gross profit | $ | 2,591 | | | $ | — | | | Operating loss | | | | | Fintech | $ | (362) | | | $ | — | | | Biotech | (540) | | | (701) | | | Corporate and other | (1,268) | | | (1,105) | | | Total Operating loss | $ | (2,170) | | | $ | (1,806) | | | Depreciation and amortization | | | | | Fintech | $ | 728 | | | $ | — | | | Biotech | 482 | | | 639 | | | Corporate and other | — | | | — | | | Total Depreciation and amortization | $ | 1,210 | | | $ | 639 | | | Interest expense, net | | | | | Fintech | $ | 376 | | | $ | — | | | Biotech | — | | | 252 | | | Corporate and other | 344 | | | — | | | Total Interest expense, net | $ | 720 | | | $ | 252 | | | Net loss before income taxes | | | | | Fintech | $ | (346) | | | $ | — | | | Biotech | (540) | | | (701) | | | Corporate and other | (1,690) | | | (1,518) | | | Total Net income before income taxes | $ | (2,576) | | | $ | (2,219) | |
|